A bottle of Genzyme Corp.'s chronic kidney disease treatment Hecterol is arranged for a photo at New London Pharmacy in New York. Photographer: JB Reed/Bloomberg
A bottle of Genzyme Corp.'s chronic kidney disease treatment Hecterol is arranged for a photo at New London Pharmacy in New York. Photographer: JB Reed/Bloomberg
%7Cutmccn%3D(direct)%7Cutmcmd%3D(none);&utmn=549146206&utmp=%2Fphoto%2F2011-02-01%2Fsanofi-talks-said-to-value-genzyme-at-20-billion-including-drug-sale-fees&utmhn=10.248.179.17&utmac=UA-11413116-12&utmhid=563200868)